ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2081 • ACR Convergence 2022

    COVID-19 Infections, Morbidity, and Seroreactivity in SLE Patients Following Initial Vaccination Series and Additional Dose Through the New York City Omicron BA.1 Wave

    Amit Saxena1, Alexis Engel2, Brittany Banbury1, Ghadeer Hasan3, Nicola Fraser1, Devyn Zaminski1, Mala Masson4, Rebecca Haberman5, Jose Scher2, Gary Ho6, Jammie Law3, Paula Rackoff1, Chung-E Tseng5, H Michael Belmont1, Robert Clancy1, Jill Buyon7 and Peter Izmirly7, 1NYU School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3NYU Langone, New York, NY, 4NYU Langone Medical Center- Division of Rheumatology, New York, NY, 5NYU Langone Health, New York, NY, 6New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, 7NYU Grossman School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at high risk for severe disease from COVID-19 and decreased vaccine efficacy, due to inherent immune perturbations…
  • Abstract Number: 2086 • ACR Convergence 2022

    Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

    Ann E Clarke1, Manuel Ugarte-Gil2, Megan Barber3, John Hanly4, Murray Urowitz5, Yvan St. Pierre6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Sasha Bernatsky6, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33, Bernardo Pons-Estel34 and Graciela Alarcón35, 1University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 7Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 10Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 35The University of Alabama at Birmingham, Oakland

    Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
  • Abstract Number: 2080 • ACR Convergence 2022

    Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample

    Rashmi Dhital1, Monica Guma2, Brian Pedersen1, Ashbina Pokharel3 and Kenneth Kalunian4, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3William Beaumont Hospital, Royal Oak, MI, 4University of California San Diego, La Jolla, CA

    Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…
  • Abstract Number: 2084 • ACR Convergence 2022

    COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Systemic Lupus Erythematosus

    Naveen R1, Elena Nikiphorou2, Mrudula Joshi3, Parikshit Sen4, Vishwesh Agarwal5, Sinan Kardes6, James B. Lilleker7, Hector Chinoy8, Oliver Distler9, Minchul Kim10, Ai Lyn Tan11, Samuel Shinjo12, Babur Salim13, Tamer A Gheita14, Nelly Ziade15, Tsvetelina Velikova16, Tulika Chatterjee10, Arvind Nune17, Marcin Milchert18, Abraham Edgar Gracia-Ramos19, Albert Selva O’Callaghan20, Miguel Angel Saavedra Salinas21, Lorenzo Cavagna22, Masataka Kuwana23, Johannes Knitza24, Jessica Day25, Ashima Makol26, Rohit Aggarwal27, Vikas Agarwal1, Latika Gupta28, Lisa S Traboco29, CoVAD Study Group30 and Ioannis Parodis31, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Leiden University Medical Center & King's College London, London, United Kingdom, 3Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, 4Maulana Azad Medical College, New Delhi, India, 5Mahatma Gandhi Missions Medical College, Lucknow, India, 6Istanbul University, Istanbul, Turkey, 7The University of Manchester, Manchester, United Kingdom, 8The University of Manchester, Sale, United Kingdom, 9Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 10University of Illinois College of Medicine Peoria, Peoria, IL, 11University of Leeds, Leeds, United Kingdom, 12Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 13Fauji foundation hospital Rawalpindi, Rawalpindi, Pakistan, 14Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, 15Saint-Joseph University, Beirut, Lebanon, 16Sofia University St. Kliment Ohridski, Sofia, Bulgaria, 17Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, 18Pomeranian Medical University in Szczecin, Szczecin, Poland, 19Instituto Mexicano del Seguro Social, Ciudad de México, Mexico, 20Hospital Universitari Vall d'Hebron, Barcelona, Spain, 21IMSS, Ciudad de México, Mexico, 22Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy, 23Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 24Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 25Walter and Eliza Hall Institute, Melbourne, Australia, 26Mayo Clinic, Rochester, MN, Rochester, MN, 27Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 28Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, 29St Luke's Medical Center - BGC, Manila, Philippines, 30CoVAD study group, Wolwehampton, United Kingdom, 31Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The COVID-19 vaccination in autoimmune diseases (COVAD) study is a large-scale real-world survey on COVID-19 vaccine safety in autoimmune rheumatic diseases (AIRDs), including systemic…
  • Abstract Number: 2085 • ACR Convergence 2022

    Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study

    Chi Chiu Mok1, Kar Li Chan2, Ling Yin Ho3 and Chi Hung To4, 1Tuen Mun Hospital, Hong Kong, China, 2Tuen Mun Hospital, Tsing Yi, Hong Kong, China, 3Tuen Mun Hospital, Hong Kong SAR, China, 4Pok Oi Hospital, Hong Kong, Hong Kong

    Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
  • Abstract Number: 2079 • ACR Convergence 2022

    Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus

    Wils Nielsen1, Vibeke Strand2, Lee S Simon3, Julian Thumboo4, Marta Mosca5, Martin Aringer6, Sindu Johnson7, Aaron Drucker7, Eric Morand8, Ian N. Bruce9 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2Stanford University School of Medicine, Stanford, CA, 3SDG LLC, West Newton, MA, 4Singapore General Hospital, Bukit Merah, Singapore, 5Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 6University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 7University of Toronto, Toronto, ON, Canada, 8Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, 9Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: The development of a Core Outcome domain Set (COS) can aid research communication and standardizing measurement tools of SLE. A COS captures SLE facets…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • Abstract Number: 2032 • ACR Convergence 2022

    Major Salivary Gland Ultrasound and Elastography for Assessment of Disease Activity in Patients of Primary Sjögren’s Syndrome

    Kunal Chandwar1, Juhi Dixit1, Kriti Kishor1, DOGGA PRASANNA KUMAR2, DIGVIJAY EKBOTE3, PUNEET KUMAR1 and Urmila Dhakad1, 1King George's Medical University, Lucknow, India, 2KGMU, LUCKNOW, Uttar Pradesh, India, 3KING GEORGE MEDICAL UNIVERSITY, LUCKNOW, Uttar Pradesh, India

    Background/Purpose: To assess major salivary gland involvement by ultrasonography and elastography in patients with Sjögren's syndrome , compare it with controls and correlate the severity…
  • Abstract Number: 2071 • ACR Convergence 2022

    The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase

    Burak Kundakci1, Megan R W Barber2, Ann E Clarke2, Sindhu R. Johnson3, Hermine Brunner4, Jiacai Cho5, Nathalie Costedoat-Chalumeau6, Ellen M. Ginzler7, John Hanly8, Abida Hasan7, Murat İnanç9, Naureen Kabani7, Alexandra Legge10, Kaitlin Lima11, Livia Lindoso12, Anselm Mak13, Rosalind Ramsey-Goldman11, Guillermo Ruiz-Irastorza14, Clovis A. Silva12, Farah Tamirou15, Vitor C. Trindade12, Evelyne Vinet16 and Ian N. Bruce1, 1Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 2University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 3Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, 4Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 5National University Health System (NUHS), Singapore, Singapore, 6Inserm DR Paris 5, Paris, France, 7SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 8Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 9Istanbul University Faculty of Medicine, Istanbul, Turkey, 10Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, 11Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 12Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, 13Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 14Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 15Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 16McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: The SLICC, ACR and LFA embarked on a data- and expert-driven project to develop a revised systemic lupus erythematosus (SLE) organ damage index (SDI).…
  • Abstract Number: 1938 • ACR Convergence 2022

    Current Approach to COVID-19 and Other Vaccinations in Children with Previous Multisystem Inflammatory Syndrome (MIS-C): An International Survey

    Francesca Minoia1, Federica Lucioni1, Merav Heshin-Bekenstein2, Sebastiaan Vastert3, Christoph Kessel4, Yosef Uziel5, Lovro Lamot6, Nicola Ruperto7, Marco Gattorno8, Claudia Bracaglia9 and Natasa Toplak10, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 2Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 3Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, 5Meir Medical Center, Kfar Saba; Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, 6University Hospital Center Zagreb, Zagreb, Croatia, 7IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, 8Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, 9Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 10University Children's Hospital, University Medical Centre, Ljubljana, Slovenia

    Background/Purpose: Following the Coronavirus Disease-19 (COVID-19) pandemic outbreaks, the hyperinflammatory condition termed Multisystem Inflammatory Syndrome in Children (MIS-C) has become a healthcare issue worldwide. Since…
  • Abstract Number: 2058 • ACR Convergence 2022

    Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus

    Stefan Perera1, Jiandong Su2, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, Joan Wither1, May Choi6, Simone Appenzeller7, Dorcas Beaton8, Dennisse Bonilla2, Patricia Katz9, Robin Green5, Michelle Barraclough10 and Zahi Touma2, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, São Paulo, Brazil, 8Institute for Work & Health, Toronto, ON, Canada, 9UCSF, San Rafael, CA, 10Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
  • Abstract Number: 2082 • ACR Convergence 2022

    A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy

    Dario Roccatello1, Savino Sciascia2, Carla Naretto1, Mirella Alpa1, Roberta Fenoglio1, Michela Ferro1, Giacomo Quattrocchio1, Elena Rubini1, Elnaz Rahbani1, Vittorio Modena1 and Daniela Rossi1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
  • Abstract Number: 2067 • ACR Convergence 2022

    Predictors of Organ Damage Accrual by Domains

    Rangi Kandane-Rathnayake1, Ning Li1, Vera Golder1, Worawit Louthrenoo2, Yi-Hsin Chen3, Jiacai Cho4, Aisha Lateef5, Laniyati Hamijoyo6, Luo Shue Fen7, Yeong-Jian Wu7, Sandra Navarra8, Leonid Zamora9, Zhanguo Li10, An Yuan11, Sargunan Sockalingam12, Yasuhiro Katsumata13, Masayoshi Harigai13, Yanjie Hao14, Zhouli Zhang15, Madelynn Chan16, Jun Kikuchi17, Tsutomu Takeuchi18, Shereen Oon19, Sang-Cheol Bae20, Fiona Goldblatt21, Sean O'Neill22, Kathy Gibson22, Kristine Ng23, Hui Nee Annie Law24, Duminda Basnayake25, Nicole Tugnet26, Sunil Kumar27, Cherica Tee28, Michael Tee28, Yoshiya Tanaka29, Chak Sing30, Mandana Nikpour31, Alberta Hoi32 and Eric Morand33, 1Monash University, Clayton, Australia, 2Chiang Mai University, Chiang Mai, Thailand, 3Taichung Veterans General Hospital, Taichung, Taiwan, 4National University Health System (NUHS), Singapore, Singapore, 5National University Hospital, Singapore, Singapore, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taoyuan, Taiwan, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Tomas Hospital, Manila, Philippines, 10People's Hospital, Peking University Health Science Center, Beijing, China, 11Peking University Health Science Center, Beijing, China, 12University of Malaya, Kuala Lumpur, Malaysia, 13Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 14The University of Melbourne, Melbourne, Australia, 15Peking University First Hospital, Beijing, China, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Keio University, Tokyo, Japan, 18Keio University and Saitama Medical University, Tokyo, Japan, 19St Vincent's Hospital, Fitzroy, Australia, 20Hanyang University Medical Center, Seoul, Republic of Korea, 21Flinders Medical Centre, Adelaide, Australia, 22Liverpool Hospital, Sydney, Australia, 23North Shore Hospital, Auckland, New Zealand, 24Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 25Teaching Hospital Kandy, Kandy, Sri Lanka, 26Greenlane Clinical Centre, Auckland, New Zealand, 27Middlemore Hospital, Auckland, New Zealand, 28University of the Philippines, Quezon City, Philippines, 29University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 30The University of Hong Kong, Pok Fu Lam, Hong Kong, 31The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, 32Monash Health, Melbourne, Australia, 33Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia

    Background/Purpose: Prevention of organ damage is one of the main treatment goals in systemic lupus erythematosus (SLE).The SLICC/ACR Damage Index (SDI) is used to quantify…
  • Abstract Number: 2043 • ACR Convergence 2022

    What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?

    Eléonore Bettacchioli1, Alain Saraux2, Alice Tison3, Divi CORNEC4, Maryvonne Dueymes1, Marta Alarcon-Riquelme5 and Valerie Devauchelle6, 1Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, 2CHU Brest, Brest, France, 3Rheumatology Department, CHRU Brest, Brest, France, 4CHRU Brest, Brest, France, 5Center for Genomics and Oncological Research (GENYO), Granada, Spain, 6Université de Bretagne Occidentale, Brest, France

    Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
  • Abstract Number: 2033 • ACR Convergence 2022

    Novel Autoantibodies Identified in Seronegative Sjögren’s Disease Using Innovative Whole Peptidome Array Technology

    Maxwell Parker, Zihao Zheng, Quinn Parker, Addie Vande Loo, Michael Newton, Miriam Shelef and Sara McCoy, University of Wisconsin, Madison, WI

    Background/Purpose: SjD disease (SjD) is typically diagnosed by the presence of an anti-SSA antibody or focal lymphocytic sialadenitis in salivary gland tissue. Among SjD patients…
  • « Previous Page
  • 1
  • …
  • 421
  • 422
  • 423
  • 424
  • 425
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology